8-butoxy-7-methoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid | 282089-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-butoxy-7-methoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid
• 英文别名: 8-butoxy-7-methoxy-2-oxo-1H-quinoline-3-carboxylic acid
• CAS: 282089-63-8
• 化学式: C₁₅H₁₇NO₅
• 分子量: 291.304
• InChiKey: DXTCQUPFKZNOLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-butoxy-7-methoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 3.5h， 生成 8-butoxy-N-(2-fluoro-2-phenylethyl)-7-methoxy-2-oxo-1H-quinoline-3-carboxamide
  参考文献：
  名称：

  Fluorinated cannabinoid CB2 receptor ligands: Synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives

  摘要：

  Cannabinoid receptor 2 (CB2) plays an important role in human physiology and the pathophysiology of different diseases, including neuroinflammation, neurodegeneration, and cancer. Several classes of CB2 receptor ligands, including 2-oxoquinoline derivatives, have been previously reported. We report the synthesis and results of in vitro receptor binding of a focused library of new fluorinated 2-oxoquinoline CB2 ligands. Twelve compounds, 13-16 18, 19, 21-24, 27, and 28 were synthesized in good yields in multiple steps. Human U87 glioma cells expressing either hCB1 (control) or hCB2 were generated via lentiviral transduction. In vitro competitive binding assay was performed using [H-3]CP-55,940 in U87hCB1 and U87hCB2 cells. Inhibition constant (K-i) values of compounds 13-16, 18, 19, 21-24, 27, and 28 for CB2 were >10,000,2.8, 5.0, 2.4, 22, 0.8, 1.4, >10,000, 486, 58, 620, and 2400 nM, respectively, and those for CB1 were >10,000 nM. Preliminary in vitro results suggest that six of these compounds may be useful for therapy of neuropathic pain, neuroinflammatory diseases and immune disorders. In addition, compound 19, with its subnanomolar K-i value, could be radiolabeled with F-18 and explored for PET imaging of CB2 expression. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.07.062
• 作为产物：
  描述：

  3-Butoxy-4-methoxy-2-nitrobenzaldehyde 在 哌啶 、 盐酸 、 水 、 铁粉 、 溶剂黄146 作用下， 以 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 16.25h， 生成 8-butoxy-7-methoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  Fluorinated cannabinoid CB2 receptor ligands: Synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives

  摘要：

  Cannabinoid receptor 2 (CB2) plays an important role in human physiology and the pathophysiology of different diseases, including neuroinflammation, neurodegeneration, and cancer. Several classes of CB2 receptor ligands, including 2-oxoquinoline derivatives, have been previously reported. We report the synthesis and results of in vitro receptor binding of a focused library of new fluorinated 2-oxoquinoline CB2 ligands. Twelve compounds, 13-16 18, 19, 21-24, 27, and 28 were synthesized in good yields in multiple steps. Human U87 glioma cells expressing either hCB1 (control) or hCB2 were generated via lentiviral transduction. In vitro competitive binding assay was performed using [H-3]CP-55,940 in U87hCB1 and U87hCB2 cells. Inhibition constant (K-i) values of compounds 13-16, 18, 19, 21-24, 27, and 28 for CB2 were >10,000,2.8, 5.0, 2.4, 22, 0.8, 1.4, >10,000, 486, 58, 620, and 2400 nM, respectively, and those for CB1 were >10,000 nM. Preliminary in vitro results suggest that six of these compounds may be useful for therapy of neuropathic pain, neuroinflammatory diseases and immune disorders. In addition, compound 19, with its subnanomolar K-i value, could be radiolabeled with F-18 and explored for PET imaging of CB2 expression. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.07.062

文献信息

• Antipruritics
  申请人：Yasui Kiyoshi

  公开号：US20050101590A1

  公开（公告）日：2005-05-12

  It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.

  这意味着它旨在提供止痒药（用于控制瘙痒的药物，抗瘙痒剂和止痒药）。研究发现，具有激动性作用的大麻素受体的化合物具有止痒效果。
• 2-oxoquinoline compounds and pharmaceutical uses thereof
  申请人：——

  公开号：US20030191069A1

  公开（公告）日：2003-10-09

  A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]: 1 (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its pharmaceutically acceptable salts selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or antiallergic action. Therefore, these compounds are useful as cannabinoid receptors (particularly peripheral type cannabinoid receptors) modulator, immunosuppressants, anti-inflammatory agents, and antiallergic agents.

  一种2-氧基喹啉化合物或其药学上可接受的盐，其通式为[I]:1（其中公式中的每个符号如说明中所确定的那样），以及其医药用途。本发明的化合物[I]及其药学上可接受的盐，能够选择性地作用于大麻素受体，特别是外周型大麻素受体，并且对中枢神经系统的副作用较少，具有很强的免疫抑制作用、抗炎作用或抗过敏作用。因此，这些化合物可用作大麻素受体（特别是外周型大麻素受体）调节剂、免疫抑制剂、抗炎剂和抗过敏剂。
• 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF
  申请人：Japan Tobacco Inc.

  公开号：EP1142877A1

  公开（公告）日：2001-10-10

  A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]: (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its pharmaceutically acceptable salts selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or antiallergic action. Therefore, these compounds are useful as cannabinoid receptors (particularly peripheral type cannabinoid receptors) modulator, immunosuppressants, anti-inflammatory agents, and antiallergic agents.

  通式[I]的 2-氧代喹啉化合物或其药学上可接受的盐： (其中式中各符号由说明中确定）及其药物用途。 本发明的化合物[I]及其药学上可接受的盐选择性地作用于大麻素受体，特别是外周型大麻素受体，对中枢神经系统的副作用较小，具有很好的免疫抑制作用、抗炎作用或抗过敏作用。因此，这些化合物可用作大麻素受体（特别是外周型大麻素受体）调节剂、免疫抑制剂、抗炎剂和抗过敏剂。
• REMEDIES FOR PRURITUS
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1447094A9

  公开（公告）日：2005-09-07

  The invention aims to find out a novel pharmacological effect (medical use) of cannabinoid. Since cannabinoid agonists such as palmidrol and anandamide have an excellent antipruritic effect, they are useful as an agent for treating any types of pruritus such as ocular pruritus, skin pruritus and systemic pruritus.

  本发明旨在发现大麻素的一种新型药理作用（医疗用途）。由于大麻素激动剂（如棕榈醇和安乃近）具有极佳的止痒效果，因此可作为治疗任何类型瘙痒症（如眼部瘙痒症、皮肤瘙痒症和全身性瘙痒症）的药物。
• ANTIPRURITICS
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1477186A1

  公开（公告）日：2004-11-17

  It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.

  其目的是提供止痒药（控制瘙痒的药物、止痒剂和止痒药）。研究发现，一种对大麻素受体具有激动活性的化合物具有止痒效果。